Harvard and MIT researchers have suggested an engineered live biotherapeutic (eLBP) may protect the gut microbiome against antibiotic-induced dysbiosis.
Bacthera, the joint venture between Chr. Hansen and Lonza, is to team up with Seres Therapeutics to manufacture Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI).
Live biotherapeutic products (LBPs) have been hailed as the answer for patients suffering from Irritable Bowel Syndrome (IBS), says GlobalData, which cite a lack of defined regulations as the main barrier to progress.
‘Designer’ biotherapeutics rationally designed to address the dysbiotic microbiome seen in Crohn’s disease and ulcerative colitis may be the ‘breakthrough’ researchers are looking for in tackling these conditions.
Newly formed NovoBiome becomes the latest firm to delve into the gut microbiome as it aims to harness Artificial Intelligence (AI) to develop Live Biotherapeutic Products (LBPs) that address liver conditions.
There is an urgent need for clarification of concepts and constraints of the probiotics used in Live Biotherapeutic (LBP) products with success dependent on credible safety and efficacy demonstrations, says a European authority.
The investment unit of healthcare giants Bayer are to invest €14m ($17m) in biotech firm Azitra to develop live therapeutic products (LBPs) that address skin disorders like atopic dermatitis and acne.
French biotech firm LNC Therapeutics is to change its name to YSOPIA Bioscience in a move designed to reflect a change in research direction towards drugs that harness the gut microbiome’s potential.
New recommendations that address the safety of biological products containing live microorganisms, may help firms obtain a marketing authorisation that is so far proving elusive, according to a research team